ArticleBriefings in bioinformatics2026
DTAP: a unified graph transformer framework for joint prediction of drug-target affinity and docking pose.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Predicting drug-target interactions (DTIs) is crucial for modern drug discovery. However, existing machine learning models have significant limitations: they are typically designed for a single task-either predicting binding affinity or docking pose-leading to excellent performance on one metric but limited practical utility. These models also often struggle with generalizability to novel molecules and proteins due to their reliance on small, labeled datasets. Furthermore, they frequently ignore the essential information contained within the 3D structure of proteins and molecules. To overcome these challenges, we introduce DTAP, a unified framework that simultaneously predicts both the quality of docking poses and drug-target binding affinity. To boost its generalizability, DTAP leverages pretrained large models to learn rich, contextual representations of drugs and targets from extensive unlabeled data. The framework also directly incorporates 3D structural data from both molecules and proteins, using two graph transformers to learn their joint representations. A shared latent vector and task-specific decoders enable crucial cross-task knowledge transfer, allowing the model to learn from the interconnected nature of these two properties. DTAP significantly outperforms state-of-the-art methods on both tasks, demonstrating superior performance especially in cold start situations where data are scarce. Our interpretability analysis on the model's attention mechanisms confirms its ability to effectively focus on key binding sites. All results indicate that DTAP is a valuable and practical tool for accurately predicting drug-target affinities and docking poses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.